Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.76 |
| ▸ | ERBB2 | P04626 | 12/20 | 0.76 |
| ▸ | ERBB4 | Q15303 | 6/20 | 0.76 |
| ▸ | GAK | O14976 | 1/20 | 0.72 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.72 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.72 |
| ▸ | LCK | P06239 | 1/20 | 0.72 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.72 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.72 |
| ▸ | SRC | P12931 | 1/20 | 0.72 |
| ▸ | DRD2 | P14416 | 1/20 | 0.72 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.72 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.72 |
| ▸ | MC3R | P41968 | 1/20 | 0.72 |
| ▸ | JAK3 | P52333 | 1/20 | 0.72 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.72 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.72 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.72 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7836821 | 1.00 | EGFR (0.76) | EGFRERBB2ERBB4GAKRIPK2 | |
| SCHEMBL7837886 | 0.94 | EGFR (0.67) | EGFRERBB2ERBB4GAKRIPK2 | |
| SCHEMBL7834343 | 0.94 | EGFR (0.67) | EGFRERBB2ERBB4GAKRIPK2 | |
| SCHEMBL5253571 | 0.94 | EGFR (0.67) | EGFRERBB2ERBB4GAKRIPK2 | |
| SCHEMBL5253715 | 0.94 | EGFR (0.67) | EGFRERBB2ERBB4GAKRIPK2 | |
| SCHEMBL7262760 | 0.91 | EGFR (0.76) | EGFRERBB2ERBB4GAKRIPK2 | |
| SCHEMBL7262756 | 0.91 | EGFR (0.76) | EGFRERBB2ERBB4GAKRIPK2 | |
| SCHEMBL7262767 | 0.91 | EGFR (0.76) | EGFRERBB2ERBB4GAKRIPK2 | |
| SCHEMBL7230756 | 0.90 | EGFR (0.77) | EGFRERBB2ERBB4GAKRIPK2 | |
| SCHEMBL5255883 | 0.90 | EGFR (0.77) | EGFRERBB2ERBB4GAKRIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1280798-B1 | BICYCLIC HETEROCYLCES, MEDICAMENTS CONTAINING SAID COMPOUNDS, THE USE THEREOF AND METHOD FOR PRODUCING THEM | BOEHRINGER INGELHEIM PHARMA (DE) | 2007-01-03 | — | — | EP | disclosed |
| EP-1280798-A1 | BICYCLIC HETEROCYLCES, MEDICAMENTS CONTAINING SAID COMPOUNDS, THE USE THEREOF AND METHOD FOR PRODUCING THEM | Boehringer Ingelheim Pharma KG (DE) | 2003-02-05 | — | — | EP | disclosed |
| US-20010044435-A1 | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2001-11-22 | — | — | US | disclosed |
| WO-2001077104-A1 | BICYCLIC HETEROCYLCES, MEDICAMENTS CONTAINING SAID COMPOUNDS, THE USE THEREOF AND METHOD FOR PRODUCING THEM | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2001-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010044435-A1 | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them | RET, BMX, CYP11B1 | EGFR 71/4885ERBB2 25/4885ERBB4 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.